May 25, 2026
AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBC
AstraZeneca and Daiichi Sankyo have secured approval from the US Food and Drug Administration (FDA) for Datroway (datopotamab deruxtecan) to treat metastatic triple-negative breast cancer (TNBC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







